Egetis Therapeutics AB (EGTX) NPV

Sell:6.08 SEKBuy:6.11 SEK0.19 SEK (3.02%)

Prices delayed by at least 15 minutes
Sell:6.08 SEK
Buy:6.11 SEK
Change:0.19 SEK (3.02%)
Deal now
Prices delayed by at least 15 minutes
Sell:6.08 SEK
Buy:6.11 SEK
Change:0.19 SEK (3.02%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

Key people

Nicklas Westerholm
Chief Executive Officer
Yilmaz Mahshid
Chief Financial Officer
Anny Bedard
President of Egetis North America
Katayoun Welin-Berger
Vice President - Technical Operations
Karl Hard
Vice President, Head - Investor Relations and Communications
Henrik Krook
Vice President - Commercial Operations
Christian Sonesson
Vice President - Product Strategy and Development
Nils Hallen
Human Resources Manager
Kristina Sjoeblom Nygren
Chief Medical Officer
Thomas Loenngren
Independent Chairman of the Board
Mats Blom
Independent Director
Gunilla Osswald
Independent Director
Elisabeth Svanberg
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Sweden
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    SE0003815604
  • Market cap
    SEK 2.26bn
  • Employees
    33
  • Shares in issue
    292.57m
  • Exchange
    Stockholm Stock Exchange
  • Index
    SX All Share PI Market Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.